Bellecapital International Ltd. Grows Position in AbbVie Inc. $ABBV

Bellecapital International Ltd. increased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 5.7% in the third quarter, Holdings Channel reports. The firm owned 65,843 shares of the company’s stock after buying an additional 3,563 shares during the period. AbbVie comprises 2.5% of Bellecapital International Ltd.’s investment portfolio, making the stock its 17th largest holding. Bellecapital International Ltd.’s holdings in AbbVie were worth $15,245,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Apollon Financial LLC boosted its stake in AbbVie by 17.0% during the third quarter. Apollon Financial LLC now owns 1,482 shares of the company’s stock worth $343,000 after buying an additional 215 shares during the period. Apollon Wealth Management LLC lifted its holdings in shares of AbbVie by 1.9% in the 3rd quarter. Apollon Wealth Management LLC now owns 82,045 shares of the company’s stock worth $18,997,000 after acquiring an additional 1,528 shares during the last quarter. 180 Wealth Advisors LLC boosted its position in shares of AbbVie by 13.0% during the 3rd quarter. 180 Wealth Advisors LLC now owns 2,686 shares of the company’s stock worth $622,000 after purchasing an additional 310 shares during the period. Columbus Macro LLC increased its holdings in AbbVie by 4.3% in the 3rd quarter. Columbus Macro LLC now owns 29,026 shares of the company’s stock valued at $6,721,000 after purchasing an additional 1,203 shares during the last quarter. Finally, Hengehold Capital Management LLC raised its position in AbbVie by 2.8% in the third quarter. Hengehold Capital Management LLC now owns 27,391 shares of the company’s stock valued at $6,342,000 after purchasing an additional 751 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Berenberg Bank raised AbbVie from a “hold” rating to a “buy” rating and increased their target price for the stock from $170.00 to $270.00 in a research note on Wednesday, September 17th. Raymond James Financial set a $256.00 price target on shares of AbbVie in a research report on Monday, November 3rd. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price objective for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. Hsbc Global Res upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. Finally, UBS Group raised their price target on shares of AbbVie from $195.00 to $220.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $245.84.

AbbVie Price Performance

AbbVie stock opened at $230.07 on Friday. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The stock has a market capitalization of $406.63 billion, a PE ratio of 174.30, a price-to-earnings-growth ratio of 1.31 and a beta of 0.36. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60. The business has a 50 day simple moving average of $226.73 and a 200-day simple moving average of $212.57.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same period last year, the firm earned $3.00 EPS. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s dividend payout ratio is 496.97%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.